NOVO B Novo Nordisk A/S Class B

Novo Nordisk – major shareholder announcement

Novo Nordisk – major shareholder announcement

Bagsværd, Denmark, 14 March 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act.

The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to below 5% of the entire share capital and below 5% of the voting rights.

For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Further information

Media:   
Ambre Brown Morley
Michael Bachner (US)     
   
Investors:   
Daniel Muusmann Bohsen    
Ann Søndermølle Rendbæk    
David Heiberg Landsted    
Jacob Martin Wiborg Rode    
Mark Joseph Root (US)    

Company announcement No 23 / 2022

Annex

Name% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
BlackRock Japan Co., Ltd.  Below 5%
BlackRock Investment Management, LLC  Below 5%
BlackRock Investment Management (UK) Limited  Below 5%
BlackRock Investment Management (Australia) Limited  Below 5%
BlackRock International Limited  Below 5%
BlackRock Institutional Trust Company, National Association  Below 5%
BlackRock Fund Advisors  Below 5%
BlackRock Financial Management, Inc.  Below 5%
BlackRock Asset Management North Asia Limited  Below 5%
BlackRock Asset Management Deutschland AG  Below 5%
BlackRock Asset Management Canada Limited  Below 5%
BlackRock Advisors, LLC  Below 5%
BlackRock Advisors (UK) Limited  Below 5%
BlackRock (Singapore) Limited  Below 5%
BlackRock Asset Management Ireland Limited  Below 5%
Aperio Holdings, LLC  Below 5%

Attachment



EN
14/03/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novo Nordisk A/S Class B

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS bought 6,450 shares at 312.500DKK and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Rune Majlund Dahl
  • Rune Majlund Dahl

Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst

Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).

Rune Majlund Dahl
  • Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead

Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales

We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.

Rune Majlund Dahl
  • Rune Majlund Dahl

Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression

We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch